How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about cemiplimab

Marketing authorisation indication

2.1

Cemiplimab (Libtayo, Regeneron) in combination with platinum-based chemotherapy is indicated for 'the first-line treatment of adult patients with NSCLC expressing PD-L1 (in ≥1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:

  • locally advanced NSCLC who are not candidates for definitive chemoradiation, or

  • metastatic NSCLC'.

Price

2.3

The list price of cemiplimab is £4,650 for a vial of 350 mg per 7 ml concentrate for solution for infusion (excluding VAT; BNF online accessed February 2025).

2.4

The company has a commercial arrangement. This makes cemiplimab available to the NHS with a discount and it would have also applied to this indication if cemiplimab had been recommended. The size of the discount is commercial in confidence.